Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial.

JAMA·2026
Same author

Pembrolizumab with or without chemotherapy among older adults with advanced lung adenocarcinoma: a national, nonrandomized open-label phase II trial (Alliance A171901).

Journal of the National Cancer Institute·2026
Same author

Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiation Therapy in Limited-Stage Small Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.

International journal of radiation oncology, biology, physics·2026
Same author

CALGB 140503 and the shift to sublobar resection for small, peripheral, node-negative NSCLC: historical context, secondary analyses, and next steps.

Frontiers in oncology·2026
Same author

Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.

Future oncology (London, England)·2026
Same author

Erratum: Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern United States.

JCO precision oncology·2026

Related Experiment Video

Updated: May 9, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Second-Line Therapy for Advanced NSCLC.

Jared M Weiss1, Thomas E Stinchcombe

  • 1Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7305, USA. Jared_Weiss@med.unc.edu

The Oncologist
|August 7, 2013
PubMed
Summary
This summary is machine-generated.

Advanced non-small cell lung cancer (NSCLC) treatments are improving patient survival and quality of life. Standard second-line therapies include cytotoxic agents and tyrosine kinase inhibitors (TKIs), with targeted therapies like crizotinib showing promise.

Keywords:
DocetaxelErlotinib, EGFR mutation, KRAS mutation, EML4/ALK rearrangement, ROS1 rearrangementGefitinibMET amplificationNon-small cell lung cancerPemetrexed

More Related Videos

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Experiment Videos

Last Updated: May 9, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

  • Medical Oncology
  • Pulmonology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer, often diagnosed at an advanced stage.
  • Current therapeutic advancements are extending survival and improving the quality of life for NSCLC patients.

Purpose of the Study:

  • To review current first-line and second-line treatment options for advanced non-small cell lung cancer (NSCLC).
  • To highlight the role of targeted therapies in NSCLC treatment based on specific genetic mutations.

Main Methods:

  • Literature review of clinical trials and treatment guidelines for second-line NSCLC therapy.
  • Analysis of standard cytotoxic agents (pemetrexed, docetaxel) and targeted therapies (EGFR TKIs, ALK inhibitors).

Main Results:

  • Median overall survival in second-line settings is approximately 9 months, with many patients receiving further treatment.
  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are preferred for EGFR-mutated NSCLC.
  • Crizotinib is a standard second-line treatment for EML4/ALK fusion protein rearrangements and shows promise for ROS1 rearrangements.

Conclusions:

  • Second-line therapies for advanced NSCLC have significantly improved patient outcomes.
  • Personalized medicine approaches, including targeted therapies based on genetic mutations (EGFR, ALK, ROS1), are crucial for optimizing NSCLC treatment.